Scarica l'app Stockscreener
16.10
8.93%
1.10
Dbv Technologies Adr Borsa (DBVT) Ultime notizie
DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Consensus Target Price from Brokerages - Defense World
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket - Benzinga
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq - Placera.se
DBV Technologies raises $30 million through ADS sale on Nasdaq - Investing.com
DBV Technologies Announces Sale of approximately $30 - GlobeNewswire
$30M ADS Sale: DBV Technologies Issues 2,307,692 ADSs via ATM Program on Nasdaq and Euronext Paris - Stock Titan
Biotech Stocks Lead European ADRs Higher On Wall Street - Finimize
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
DBV Technologies Announces Board Member Resignation - MSN
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
European ADRs In The US See Modest Gains On Health And Tech - Finimize
What drives DBV Technologies SA DBV stock priceLarge Cap Stability Picks & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
Can DBV Technologies S.A. Depositary Receipt stock reach $100 price target2025 Market Trends & Expert Curated Trade Ideas - newser.com
DBV Technologies Announces Resignation of Board Member - GlobeNewswire
Biotech Board Shake-up: DBV Technologies Director Exits Amid VIASKIN Peanut Patch Development - Stock Titan
DBV Technologies stock rating reiterated at Market Outperform by JMP - Investing.com
Brokerages Set DBV Technologies S.A. (NASDAQ:DBVT) Target Price at $14.75 - Defense World
Analysts Set DBV Technologies S.A. (NASDAQ:DBVT) Price Target at $14.75 - Defense World
DBV Technologies Establishes an At-The-Market Program on Nasdaq - MarketScreener
DBV Technologies Launches $150M ATM Equity Offering - The Globe and Mail
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq - Placera.se
DBV Technologies S.A. - Via Ritzau
$150 Million Financing: DBV Technologies Launches New ATM Program to Fund VIASKIN Peanut Patch Development - Stock Titan
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
Clinical-Stage Biotech DBV Technologies Featured at H.C. Wainwright Global Investment Conference - Stock Titan
Market reaction to DBV Technologies S.A. Depositary Receipt’s recent newsQuarterly Portfolio Review & High Conviction Trade Alerts - Newser
Should you hold or exit DBV Technologies S.A. Depositary Receipt nowJuly 2025 Opening Moves & Fast Entry and Exit Trade Plans - Newser
European ADRs End Lower As Healthcare And Telecom Diverge - Finimize
European ADRs: A Strategic Buy Amid Macroeconomic Shifts and Undervalued Sectors - AInvest
Will DBV Technologies S.A. Depositary Receipt continue its uptrendPortfolio Growth Summary & Long-Term Growth Stock Strategies - Newser
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
European ADRs Climb On Solid Gains From Health And Tech Stocks - Finimize
Published on: 2025-08-19 16:04:03 - Newser
Using portfolio simulators with DBV Technologies S.A. Depositary Receipt includedQuarterly Profit Report & Daily Profit Focused Screening - Newser
DBV Technologies S.A. Depositary Receipt Moves Into Bullish Territory Based on MACD2025 Market Trends & Precise Swing Trade Alerts - metal.it
DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest
Peanut Allergy Treatment Market Report 2025-2033, with Key Player Profiles for Aimmune Therapeutics, DBV Technologies, Sanofi, ALK-Abello, Prota Therapeutics, Camallergy, Aravax, and Genentech - Yahoo Finance
European ADRs Edge Higher While Sector Winners And Losers Diverge - Finimize
European ADRs Face Choppy Trading As Sentiment Sours - Finimize
Does DBV Technologies S.A. Depositary Receipt fit your quant trading modelAlpha Generation Strategy with Low Volatility - Newser
HC Wainwright Lowers Earnings Estimates for DBV Technologies - Defense World
European Stocks Dip As US Holders Turn Cautious - Finimize
DBV Technologies Maintains Buy Rating with €6.00 Target from Kepler Capital's Justine Telliez - AInvest
DBV Technologies Announces Filing of 2025 Half-Year Report - AInvest
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report - GlobeNewswire
DBV Technologies Releases Latest Financial Report: Food Allergy Treatment Progress Updates Inside - Stock Titan
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results - GlobeNewswire
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - The Manila Times
DBV Technologies Liquidity Contract Update: Over €3M in Trading Volume Reveals Market Activity - Stock Titan
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Tuesday - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Average PT from Analysts - Defense World
European ADRs Inch Higher As Drugmakers Shine - Finimize
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):